Navigation Links
Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
Date:2/13/2008

period, a decrease of 75%. This decrease resulted primarily from the final installment of license revenue under the Company's collaboration with bioMerieux, which was recognized in the prior year period. For the full year 2007, royalty and license revenues were $15.5 million, compared to $13.5 million in the prior year, an increase of 15% that resulted primarily from $10.3 million of royalty revenue that was recorded in the first quarter of 2007 associated with the successful settlement of Gen-Probe's patent infringement claims against Bayer HealthCare (now Siemens Healthcare Diagnostics).

Gross margin on product sales in the fourth quarter of 2007 was 69.2%, compared to 67.6% in the prior year period. This increase resulted primarily from reduced sales of lower-margin instrumentation compared to the prior year period. For the full year 2007, gross margin on product sales was 67.7%, compared to 68.1% in the prior year.

Research and development (R&D) expenses in the fourth quarter of 2007 were $24.3 million, compared to $20.7 million in the prior year period, an increase of 17%. This increase resulted primarily from increased labor costs and the timing of major R&D projects. These projects include assays for human papillomavirus (HPV) and healthcare-associated infections, a fully automated instrument system for low- and mid-volume laboratory customers, and the post-marketing studies for the PROCLEIX ULTRIO(R) assay in the United States. For the full year 2007, R&D expenses were $97.1 million, compared to $84.5 million in the prior year, an increase of 15% that was due primarily to the factors described above.

Marketing and sales expenses in the fourth quarter of 2007 were $11.3 million, compared to $9.6 million in the prior year period, an increase of 18%. This increase resulted primarily from European market development efforts related to the Company's investigational APTIMA HPV assay. For the full year 2007, marketing and sales expenses were $
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Carl Hull Named President and Chief Operating Officer of Gen-Probe
2. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
5. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
6. Imagenetix Inc. Reports Third Fiscal Quarter Results
7. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
8. Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
9. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , July 3, 2015 ... den 22. september 2015 på  http://www.openinnovationinscience.at ... Science", der finder sted i ... nylig undersøgelse af internationale forskere og videnskabsmænd ... de to største udfordringer for sundhedsvidenskaben manglen ...
(Date:7/2/2015)... Ill. , July 2, 2015 College ... Colton Eakins are gaining invaluable real-world experiences while ... Technology this summer. The students will be ... Jeff Wereszczynski,s research group at IIT. The internship ... Tom Carter , Physics; Dr. Kathy Finan ...
(Date:7/2/2015)... , July 2, 2015 Amici ... Bio-tech procurement company Amici Procurement has chosen Microsoft Cloud ... it move to Office 365.      (Logo: ... small to medium-sized companies in the bio-tech sector with ... of the purchasing cycle to help them obtain best ...
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech Medical ... instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ., ... of surgical instruments to the Spine Industry. The acquisition of Turner Medical ideally ...
Breaking Biology Technology:Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3COD Students Participate in Prestigious Summer Internships 2Biotech Procurement Company Moves to Office 365 with iomart 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3
... CAMBRIDGE, England , May 25, 2010 ... ) announced today,an extension of the agreement under which O2h provides multi-FTE ... , , ... , Head of Chemistry said, "We are happy to have signed,this new ...
... , PARIS , May 25, 2010 ... - NEVO(TM), Incorporating RES ... Presented at EuroPCR 2010 , , , ... At 12 months the NEVO(TM) Sirolimus-eluting Coronary Stent has continued,to demonstrate excellent safety and ...
... NEW YORK , May 25, 2010 ... microprocessor technologies for use in,portable monitoring devices, announced that ... daily activity level of an individual and specifically,for use ... obese. The bracelet,designed both for children and adults, has ...
Cached Biology Technology:Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 3NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data 2NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data 3NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data 4NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data 5SPO Medical Announces Innovative Wellness Bracelet 2SPO Medical Announces Innovative Wellness Bracelet 3SPO Medical Announces Innovative Wellness Bracelet 4SPO Medical Announces Innovative Wellness Bracelet 5
(Date:6/15/2015)... , June 15, 2015 A ... from Telstra reveals the majority of US consumers using mobile ... via biometrics, such as fingerprint and voiceprint, instead of having ... According to Telstra,s " Mobile Identity   -   ... report, with smartphones now the primary channel used by ...
(Date:6/11/2015)... 2015 Daon, a global leader in ... IdentityX Mobile Authentication Platform v4.0 has been FIDO ... an industry consortium launched in 2013 to revolutionize ... authentication.  In order to receive certification, a company,s ... of tests that measure compliance and ensure interoperability ...
(Date:6/9/2015)... Research and Markets  ( http://www.researchandmarkets.com/research/xsgs2s/gesture ) ... Recognition & Touchless Sensing Market by Technology (Touch-based ... Product (Biometric & Sanitary Equipment) & by Geography ... their offering. The total gesture recognition ... $ 23.55 Billion by 2020 at a high ...
Breaking Biology News(10 mins):One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... Signals can tell cells to act cancerous, surviving, growing ... tell cells with cancerous characteristics to stop growing or ... TGF-beta does both sometimes promoting tumors and sometimes ... study recently published in the journal Oncogene ...
... Alexandria, VA -- Today, the Association for Molecular ... (USPTO) to place a moratorium on the issuing of ... Agency hearing on genetic diagnostic testing. AMP is the ... Liberties Union (ACLU) sponsored lawsuit challenging the validity of ...
... URBANA In a worst-case scenario simulation ... that establishing a good surveillance system and raising a ... to the Mexican cattle industry should an outbreak of ... "For diseases that spread very quickly, such as foot-and-mouth, ...
Cached Biology News:Study details on-off switch that promotes or suppresses breast cancer 2AMP testifies at USPTO 2Study simulates effects of foot-and-mouth disease outbreak in Mexico 2Study simulates effects of foot-and-mouth disease outbreak in Mexico 3
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
...
...
Biology Products: